ImmunityBio, Inc.
Clinical trials sponsored by ImmunityBio, Inc., explained in plain language.
Immunotherapy biotech developing cancer treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immune booster plus standard therapy shows promise for bladder cancer Results expected Sep 2026 (estimated)
- Could an immune booster beat long COVID? small trial begins Results expected Oct 2026 (estimated)
- New bladder cancer cocktail aims to spare patients from surgery Results expected Nov 2026 (estimated)
- Immune cell cocktail takes on Platinum-Resistant ovarian cancer Results expected May 2027 (estimated)
- New immune-boosting combo targets stubborn lymphoma Results expected May 2027 (estimated)
-
New drug cocktail aims to outsmart resistant lung cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding an experimental drug (N-803) to standard chemotherapy (docetaxel) can help people with advanced non-small cell lung cancer whose disease has stopped responding to immunotherapy. About 507 participants will be randomly assigned to receive ei…
Phase 3 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Immune cell cocktail takes on Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis phase 2 trial tests a new approach for people with platinum-resistant high-grade ovarian cancer, a type that no longer responds to standard chemotherapy. Up to 20 participants will receive their own immune cells (M-CENK) that have been trained to fight cancer, along with an …
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug anktiva tested for long COVID relief
Disease control Recruiting nowThis study tests the safety of a drug called Anktiva in 40 adults with Long COVID—persistent symptoms after a COVID-19 infection. Participants receive the drug as a shot, and researchers monitor for side effects and changes in symptoms. The goal is to see if Anktiva is safe enoug…
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for bladder cancer patients: experimental BCG treatment made available
Disease control Expanded accessThis expanded access program offers a modified tuberculosis vaccine (recombinant BCG) to people with non-muscle invasive bladder cancer who cannot join a clinical trial. The treatment is given directly into the bladder and aims to control the disease. It is only for patients who …
Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could an immune booster beat long COVID? small trial begins
Disease control Recruiting nowThis Phase 2 trial tests the safety of a drug called Anktiva (N-803) in 20 adults with Long COVID. Participants get up to two shots and are monitored for side effects and changes in immune cells and quality of life. The goal is to see if the drug is safe enough to study further f…
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New immune-boosting combo targets stubborn lymphoma
Disease control Recruiting nowThis study tests a new combination of drugs (CD19 t-haNK, N-803, and rituximab) in 20 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors and improve survival. Particip…
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New immune cell combo targets hard-to-treat lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests a new type of immune cell therapy (CD19 t-haNK) alone or with two other drugs (N-803 and rituximab) in up to 20 adults with relapsed or refractory non-Hodgkin lymphoma. The main goal is to check safety, and researchers will also see if the treatment s…
Phase 1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Engineered TB bacteria could offer new hope for bladder cancer patients
Disease control Recruiting nowThis early-stage trial is testing a new version of the BCG therapy, made from a genetically modified bacterium, for people with non-muscle invasive bladder cancer (NMIBC) who have not received BCG before. The treatment is given directly into the bladder through a catheter. The st…
Phase 1/2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental drug offers hope for cancer patients with depleted immune cells
Disease control Expanded accessThis expanded access program provides nogapendekin-alfa inbakicept (NAI) to adults with solid tumors who have low lymphocyte counts caused by prior cancer treatments like chemotherapy, immunotherapy, or radiation. The goal is to reverse and maintain healthy lymphocyte levels. It …
Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC